FBN1
protein-codingfibrillin 1, the group of Fibrillins
Gene summary
This gene encodes a member of the fibrillin family of proteins. The encoded preproprotein is proteolytically processed to generate two proteins including the extracellular matrix component fibrillin-1 and the protein hormone asprosin. Fibrillin-1 is an extracellular matrix glycoprotein that serves as a structural component of calcium-binding microfibrils. These microfibrils provide force-bearing structural support in elastic and nonelastic connective tissue throughout the body. Asprosin, secreted by white adipose tissue, has been shown to regulate glucose homeostasis. Mutations in this gene are associated with Marfan syndrome and the related MASS phenotype, as well as ectopia lentis syndrome, Weill-Marchesani syndrome, Shprintzen-Goldberg syndrome and neonatal progeroid syndrome. [provided by RefSeq, Apr 2016]
- FBN
- MFS1
- WMS
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~237.4 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: Unknown
Disease ID:MONDO:0008426
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AD
Disease ID:MONDO:0008426
Submitter: ClinGen
The relationship between *FBN1* and Shprintzen-Goldberg syndrome was first reported in 1996 by Sood et al. (PMID: 8563763). However, the *FBN1* missense variant in this report has been found at a higher than expected frequency in the general population and is therefore not considered evidence in this evaluation. Two additional missense variants (PMIDs: 19293843, 27160103) have been observed at frequencies in the general population too high to be considered as evidence. Three additional variants (PMIDs: 8563763, 16333834, 19293843) were not evaluated as the clinical presentation of the affected individuals was more consistent with Marfan syndrome than Shprintzen-Goldberg syndrome. In 2012, heterozygous pathogenic variants in the gene *SKI* were reported as the genetic cause of Shprintzen-Goldberg syndrome (PMIDs: 23023332, 23103230). In summary, the evidence supporting a relationship between Shprintzen-Goldberg syndrome and *FBN1* is disputed. This classification was approved by the ClinGen Intellectual Disability and Autism Gene Curation Expert Panel on December 1, 2021 (SOP Version 9).
Inheritance Pattern: AD
Disease ID:MONDO:0007947
Submitter: G2P
Inheritance Pattern: AD
Disease ID:MONDO:0007947
Submitter: Genomics England PanelApp
Inheritance Pattern: AD
Disease ID:MONDO:0007055
Submitter: Orphanet
Inheritance Pattern: AD
Disease ID:MONDO:0014831
Submitter: Ambry Genetics
Inheritance Pattern: Unknown
Disease ID:MONDO:0019625
Submitter: ClinGen
Inheritance Pattern: AD
Disease ID:MONDO:0014831
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AD
Disease ID:MONDO:0012013
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AD
Disease ID:MONDO:0000127
Submitter: Orphanet
Inheritance Pattern: AR
Disease ID:MONDO:0007947
Submitter: G2P
Inheritance Pattern: AD
Disease ID:MONDO:0015998
Submitter: Orphanet
Inheritance Pattern: AD
Disease ID:MONDO:0007514
Submitter: G2P
Inheritance Pattern: AD
Disease ID:MONDO:0014831
Submitter: Orphanet
Inheritance Pattern: AD
Disease ID:MONDO:0014831
Submitter: Ambry Genetics
Inheritance Pattern: AD
Disease ID:MONDO:0007947
Submitter: Orphanet
Inheritance Pattern: AD
Disease ID:MONDO:0017309
Submitter: Orphanet
Inheritance Pattern: AD
Disease ID:MONDO:0007947
Submitter: Ambry Genetics
Inheritance Pattern: AD
Disease ID:MONDO:0012013
Submitter: G2P
Inheritance Pattern: AD
Disease ID:MONDO:0018096
Submitter: Orphanet
Inheritance Pattern: AD
Disease ID:MONDO:0008492
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AD
Disease ID:MONDO:0019625
Submitter: Orphanet
Inheritance Pattern: AD
Disease ID:MONDO:0007947
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AD
Disease ID:MONDO:0008492
Submitter: Ambry Genetics
Inheritance Pattern: AD
Disease ID:MONDO:0007055
Submitter: Ambry Genetics
Clinical Genomic Database (CGD)
Manifestation: Cardiovascular; Craniofacial; Dental; Dermatologic; Musculoskeletal; Neurologic; Ophthalmologic; Pulmonary
Intervention: Cardiovascular; Musculoskeletal; Ophthalmologic; Pharmacogenomic; Pulmonary
Rationale: Medications that reduce aortic wall hemodynamic stress (eg, beta blockers) have been shown to be effective; Afterload-reducing agents can improve cardiovascular function in CHF; Surgical aortic repair is indicated depending on parameters such as size and rate of change of aorta; Other issues also require attention and may benefit from regular surveillance, such as those involving ophthalomologic, pulmonary, and skeletal complications; Certain agents and circumstances should be avoided, including activities that impose cardiovascular or musculoskeletal risk, as well as agents such as decongestants, caffeine; LASIK is typically contraindicated; Geleophysic dysplasia may frequently be clinically recognizable, but individuals can have cardiovascular manifestations such as progressive cardiac valve thickening necessitating surgical interventions very early in childhood, and early diagnosis may be beneficial to allow early treatment; In Weill-Marchesani syndrome, awareness of the risk of certain ophthalmological complications (including glaucoma) can allow prompt awareness and treatment
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to FBN1 variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_000138.5. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 4 | 9 | 44 | 1212 | 28 | 1297 |
| missense | 556 | 1188 | 2458 | 263 | 25 | 4490 |
| nonsense | 394 | 101 | 5 | 500 | ||
| start loss | 6 | 2 | 8 | |||
| frameshift | 846 | 243 | 11 | 1100 | ||
| splice donor/acceptor (+/-2bp) | 188 | 197 | 13 | 398 | ||
| Total | 1994 | 1740 | 2531 | 1475 | 53 | 7793 |
Highest pathogenic variant AF is 0.00008426479
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_000129.3 | 65 | MANE Select | |
| Ensembl | ENSP00000325527.5 | 65 | MANE Select | |
| RefSeq | NP_001393645.1 | 65 | Standard | |
| RefSeq | NP_001393646.1 | 8 | Standard |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- Hypothesized Pathways in Pathogenesis of Cardiovascular Disease
- Post-translational protein phosphorylation
- Integrin cell surface interactions
- Post-translational protein modification
- Metabolism of proteins
Biological Process
- skeletal system development
- metanephros development
- heart development
- regulation of signaling receptor activity
- extracellular matrix organization
Molecular Function
- integrin binding
- hormone activity
- extracellular matrix structural constituent
- calcium ion binding
- protein binding
Cellular Component
- microfibril
- extracellular region
- basement membrane
- extracellular space
- endoplasmic reticulum lumen
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000316623
- Coding exons
- 65
- Length
- 237544
- Individuals with no LoFs
- 125733
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 14
- Defined
- 125747
- p
- 0.0000557
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 5.06 | 1038 | 1.61e+3 | 0.645 | 0.0000932 | 19158 |
| Missense (PolyPhen) | 346 | 757.54 | 0.45674 | 8847 | ||
| Synonymous | 0.221 | 573 | 580 | 0.988 | 0.0000365 | 5163 |
| Loss of Function | 11.5 | 3 | 159 | 0.0189 | 0.00000894 | 1983 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0 | 0.0 | absent |
| Latino/Admixed American | 0 | 0.0 | absent |
| Ashkenazi Jewish | 0 | 0.0 | absent |
| East Asian | 0 | 0.0 | absent |
| Finnish | 0.00042 | 0.00042 | rare |
| European (Non-Finnish) | 0.0000088 | 0.0000088 | rare |
| South Asian | 0.00013 | 0.000065 | rare |
| Other | 0.00033 | 0.00033 | rare |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: Fibrillin-1: Structural component of the 10-12 nm diameter microfibrils of the extracellular matrix, which conveys both structural and regulatory properties to load-bearing connective tissues (PubMed:1860873, PubMed:15062093). Fibrillin-1- containing microfibrils provide long-term force bearing structural support. In tissues such as the lung, blood vessels and skin, microfibrils form the periphery of the elastic fiber, acting as a scaffold for the deposition of elastin. In addition, microfibrils can occur as elastin-independent networks in tissues such as the ciliary zonule, tendon, cornea and glomerulus where they provide tensile strength and have anchoring roles. Fibrillin-1 also plays a key role in tissue homeostasis through specific interactions with growth factors, such as the bone morphogenetic proteins (BMPs), growth and differentiation factors (GDFs) and latent transforming growth factor-beta-binding proteins (LTBPs), cell- surface integrins and other extracellular matrix protein and proteoglycan components (PubMed:27026396). Regulates osteoblast maturation by controlling TGF-beta bioavailability and calibrating TGF-beta and BMP levels, respectively (By similarity). Negatively regulates osteoclastogenesis by binding and sequestering an osteoclast differentiation and activation factor TNFSF11. This leads to disruption of TNFSF11-induced Ca(2+) signaling and impairment of TNFSF11-mediated nuclear translocation and activation of transcription factor NFATC1 which regulates genes important for osteoclast differentiation and function (PubMed:24039232). Mediates cell adhesion via its binding to cell surface receptors integrins ITGAV:ITGB3 and ITGA5:ITGB1 (PubMed:12807887, PubMed:17158881). Binds heparin and this interaction has an important role in the assembly of microfibrils (PubMed:11461921). {ECO:0000250|UniProtKB:Q61554, ECO:0000269|PubMed:11461921, ECO:0000269|PubMed:12807887, ECO:0000269|PubMed:15062093, ECO:0000269|PubMed:17158881, ECO:0000269|PubMed:1860873, ECO:0000269|PubMed:24039232, ECO:0000303|PubMed:27026396}.;
- Disease
- DISEASE: Marfan syndrome (MFS) [MIM:154700]: A hereditary disorder of connective tissue that affects the skeletal, ocular, and cardiovascular systems. A wide variety of skeletal abnormalities occurs with Marfan syndrome, including scoliosis, chest wall deformity, tall stature, abnormal joint mobility. Ectopia lentis occurs in most of the patients and is almost always bilateral. The leading cause of premature death is progressive dilation of the aortic root and ascending aorta, causing aortic incompetence and dissection. Neonatal Marfan syndrome is the most severe form resulting in death from cardiorespiratory failure in the first few years of life. {ECO:0000269|PubMed:10425041, ECO:0000269|PubMed:10441597, ECO:0000269|PubMed:10694921, ECO:0000269|PubMed:11700157, ECO:0000269|PubMed:11826022, ECO:0000269|PubMed:12161601, ECO:0000269|PubMed:12203992, ECO:0000269|PubMed:12402346, ECO:0000269|PubMed:1301946, ECO:0000269|PubMed:14695540, ECO:0000269|PubMed:15161917, ECO:0000269|PubMed:15221638, ECO:0000269|PubMed:1569206, ECO:0000269|PubMed:16220557, ECO:0000269|PubMed:16222657, ECO:0000269|PubMed:17657824, ECO:0000269|PubMed:18435798, ECO:0000269|PubMed:1852208, ECO:0000269|PubMed:19533785, ECO:0000269|PubMed:19941982, ECO:0000269|PubMed:20803651, ECO:0000269|PubMed:21542060, ECO:0000269|PubMed:22772377, ECO:0000269|PubMed:7611299, ECO:0000269|PubMed:7738200, ECO:0000269|PubMed:7762551, ECO:0000269|PubMed:7870075, ECO:0000269|PubMed:7951214, ECO:0000269|PubMed:7977366, ECO:0000269|PubMed:8004112, ECO:0000269|PubMed:8040326, ECO:0000269|PubMed:8071963, ECO:0000269|PubMed:8136837, ECO:0000269|PubMed:8281141, ECO:0000269|PubMed:8406497, ECO:0000269|PubMed:8504310, ECO:0000269|PubMed:8863159, ECO:0000269|PubMed:8882780, ECO:0000269|PubMed:9016526, ECO:0000269|PubMed:9254848, ECO:0000269|PubMed:9338581, ECO:0000269|PubMed:9401003, ECO:0000269|PubMed:9452085, ECO:0000269|PubMed:9837823, ECO:0000269|Ref.68}. Note=The disease is caused by mutations affecting the gene represented in this entry. The majority of the more than thousand mutations in FBN1 currently known are point mutations, the rest are frameshifts and splice site mutations. Marfan syndrome has been suggested in at least 2 historical figures, Abraham Lincoln and Paganini.; DISEASE: Ectopia lentis 1, isolated, autosomal dominant (ECTOL1) [MIM:129600]: An ocular abnormality characterized by partial or complete displacement of the lens from its space resulting from defective zonule formation. {ECO:0000269|PubMed:11700157, ECO:0000269|PubMed:11826022, ECO:0000269|PubMed:12203992, ECO:0000269|PubMed:17657824, ECO:0000269|PubMed:8188302}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Weill-Marchesani syndrome 2 (WMS2) [MIM:608328]: A rare connective tissue disorder characterized by short stature, brachydactyly, joint stiffness, and eye abnormalities including microspherophakia, ectopia lentis, severe myopia and glaucoma. {ECO:0000269|PubMed:12525539}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Overlap connective tissue disease (OCTD) [MIM:604308]: Heritable disorder of connective tissue characterized by involvement of the mitral valve, aorta, skeleton, and skin. MASS syndrome is closely resembling both the Marfan syndrome and the Barlow syndrome. However, no dislocation of the lenses or aneurysmal changes occur in the aorta, and the mitral valve prolapse is by no means invariable. {ECO:0000269|PubMed:2739055}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Stiff skin syndrome (SSKS) [MIM:184900]: A syndrome characterized by hard, thick skin, usually over the entire body, which limits joint mobility and causes flexion contractures. Other occasional findings include lipodystrophy and muscle weakness. {ECO:0000269|PubMed:20375004}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Geleophysic dysplasia 2 (GPHYSD2) [MIM:614185]: An autosomal dominant disorder characterized by severe short stature, short hands and feet, joint limitations, and skin thickening. Radiologic features include delayed bone age, cone-shaped epiphyses, shortened long tubular bones, and ovoid vertebral bodies. Affected individuals have characteristic facial features including a 'happy' face with full cheeks, shortened nose, hypertelorism, long and flat philtrum, and thin upper lip. Other distinctive features include progressive cardiac valvular thickening often leading to an early death, toe walking, tracheal stenosis, respiratory insufficiency, and lysosomal-like storage vacuoles in various tissues. {ECO:0000269|PubMed:21683322}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Acromicric dysplasia (ACMICD) [MIM:102370]: An autosomal dominant disorder characterized by severe short stature, short hands and feet, joint limitations, and skin thickening. Radiologic features include delayed bone age, cone-shaped epiphyses, shortened long tubular bones, and ovoid vertebral bodies. Affected individuals have distinct facial features, including round face, well-defined eyebrows, long eyelashes, bulbous nose with anteverted nostrils, long and prominent philtrum, and thick lips with a small mouth. Other characteristic features include hoarse voice and pseudomuscular build, and there are distinct skeletal features as well, including an internal notch of the femoral head, internal notch of the second metacarpal, and external notch of the fifth metacarpal. {ECO:0000269|PubMed:21683322}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Marfan lipodystrophy syndrome (MFLS) [MIM:616914]: A syndrome characterized by congenital lipodystrophy, a progeroid facial appearance due to lack of subcutaneous fat, and variable signs of Marfan syndrome. Clinical features include premature birth with an accelerated linear growth disproportionate to the weight gain, ectopia lentis, aortic dilatation, dural ectasia, and arachnodactyly. Mental and motor development are within normal limits. {ECO:0000269|PubMed:20979188, ECO:0000269|PubMed:21594992, ECO:0000269|PubMed:21594993, ECO:0000269|PubMed:24039054, ECO:0000269|PubMed:24613577, ECO:0000269|PubMed:24665001, ECO:0000269|PubMed:26860060, ECO:0000269|PubMed:27087445}. Note=The disease is caused by mutations affecting the gene represented in this entry. Asprosin: Mutations specifically affect Asprosin, a hormone peptide present at the C-terminus of Fibrillin-1 chain, which is cleaved from Fibrillin-1 following secretion (PubMed:27087445). {ECO:0000269|PubMed:27087445}.;
Recessive Scores
- pRec
- 0.114
Intolerance Scores
- LoFtool
- 0.00289
- RVIS EVS
- -2.81
- RVIS percentile EVS
- 0.64
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- N
- Essential (gene trap)
- N
- Indispensability pred.
- E
- Indispensability score
- 0.748
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |